Top-Rated StocksTop-RatedTop MarketRank™ StocksTop MarketRank™NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $141.91 -1.54 (-1.07%) (As of 11:08 AM ET) Add Compare Share Share Today's Range$141.24▼$144.2250-Day Range$116.83▼$163.8552-Week Range$55.25▼$173.25Volume122,311 shsAverage Volume1.37 million shsMarket Capitalization$13.41 billionP/E Ratio1,290.09Dividend YieldN/APrice Target$186.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sarepta Therapeutics alerts: Email Address Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside29.8% Upside$186.22 Price TargetShort InterestHealthy7.11% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.65Based on 14 Articles This WeekInsider TradingSelling Shares$7.58 M Sold Last QuarterProj. Earnings Growth146.28%From $3.76 to $9.26 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.94 out of 5 starsMedical Sector11th out of 924 stocksPharmaceutical Preparations Industry4th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 16 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.11% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 8.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 2.6 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Sarepta Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 25 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -41% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold 52.90% more of their company's stock than they have bought. Specifically, they have bought $4,955,684.00 in company stock and sold $7,577,486.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 146.28% in the coming year, from $3.76 to $9.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 1,304.09, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 1,304.09, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 139.67.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 15.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsSecure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.Click here for the ticker >>> About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesAugust 21 at 6:03 AM | insidertrades.comInsider Buying: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Acquires 37,038 Shares of StockAugust 19 at 8:00 AM | marketbeat.comThis Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.August 22, 2024 | Stansberry Research (Ad)Famous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.August 20 at 5:02 PM | insidermonkey.comHedge Fund and Insider Trading News: Michael Burry, Scott Bessent, David Goel, Bill Ackman, Paloma Partners, Valiant Capital, Rhenman & Partners Asset Management, Sarepta Therapeutics Inc (SRPT), Sunrise Realty Trust Inc (SUNS), and MoreAugust 19 at 12:38 AM | finance.yahoo.comSRPT Aug 2024 128.000 put (SRPT240823P00128000)August 18, 2024 | americanbankingnews.comSarepta Therapeutics' (SRPT) Outperform Rating Reiterated at Royal Bank of CanadaAugust 16, 2024 | benzinga.comHow Is The Market Feeling About Sarepta Therapeutics?August 15, 2024 | benzinga.comA Closer Look at 28 Analyst Recommendations For Sarepta TherapeuticsAugust 22, 2024 | Stansberry Research (Ad)Famous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.August 15, 2024 | forbes.comBiotech Stock Flashing Bull SignalAugust 14, 2024 | finance.yahoo.comShareholders In Sarepta Therapeutics (NASDAQ:SRPT) Should Look Beyond Earnings For The Full StoryAugust 12, 2024 | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)August 12, 2024 | finance.yahoo.comSome Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Analysts Just Made A Major Cut To Next Year's EstimatesAugust 12, 2024 | fool.com2 Biotech Stocks to Buy Hand Over Fist in AugustAugust 12, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Evercore ISIAugust 12, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $181.00August 12, 2024 | americanbankingnews.comSarepta Therapeutics, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.12) Per Share (NASDAQ:SRPT)August 9, 2024 | markets.businessinsider.comHold Rating on Sarepta Therapeutics Amidst Elevidys Sales Uncertainty and Revised Target PriceSee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today8/21/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$186.22 High Stock Price Target$235.00 Low Stock Price Target$109.00 Potential Upside/Downside+29.8%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio1,304.09 Forward P/E Ratio38.15 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins1.20% Pretax Margin2.43% Return on Equity2.20% Return on Assets0.58% Debt Debt-to-Equity Ratio1.18 Current Ratio4.05 Quick Ratio3.44 Sales & Book Value Annual Sales$1.50 billion Price / Sales9.01 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book15.61Miscellaneous Outstanding Shares94,524,000Free Float87,246,000Market Cap$13.56 billion OptionableOptionable Beta0.89 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZIonis PharmaceuticalsNASDAQ:IONSMirati TherapeuticsNASDAQ:MRTXPTC TherapeuticsNASDAQ:PTCTACADIA PharmaceuticalsNASDAQ:ACADView All CompetitorsInsiders & InstitutionsTruist Financial CorpBought 1,857 shares on 8/21/2024Ownership: 0.004%Advisory Alpha LLCSold 1,370 shares on 8/21/2024Ownership: 0.001%Point72 Asset Management L.P.Sold 14,156,087 shares on 8/19/2024Ownership: 0.052%EP Wealth Advisors LLCBought 103 shares on 8/19/2024Ownership: 0.005%Michael Andrew ChambersBought 37,038 shares on 8/16/2024Total: $4.96 M ($133.80/share)View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $96.43 at the beginning of the year. Since then, SRPT stock has increased by 48.8% and is now trading at $143.45. View the best growth stocks for 2024 here. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. The company's revenue for the quarter was up 38.9% compared to the same quarter last year. What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional shareholders include Avoro Capital Advisors LLC (3.17%), Susquehanna International Group LLP, Thrivent Financial for Lutherans (0.68%) and Federated Hermes Inc. (0.54%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor, Stephen Mayo and Louise Rodino-Klapac. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA) and Netflix (NFLX). This page (NASDAQ:SRPT) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
